Siegfried Kasper
Affiliations: | Medical University of Vienna, Wien, Wien, Austria |
Google:
"Siegfried Kasper"Mean distance: 16.53 (cluster 17)
Children
Sign in to add trainee| Lukas Pezawas | research scientist | 1994-2001 | Medical University of Vienna |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| McIntyre RS, Rosenblat JD, Nemeroff CB, et al. (2021) Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. The American Journal of Psychiatry. appiajp202020081251 |
| Dold M, Bartova L, Fugger G, et al. (2021) Melancholic features in major depression - A European multicenter study. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 110285 |
| Dodd S, Bauer M, Carvalho AF, et al. (2020) A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough? The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 1-20 |
| Dold M, Bartova L, Fugger G, et al. (2020) Add-on benzodiazepine treatment in patients with major depressive disorder - results from a European cross-sectional multicenter study. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology |
| Fugger G, Dold M, Bartova L, et al. (2020) Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression. The International Journal of Neuropsychopharmacology |
| Ionescu DF, Fu DJ, Qiu X, et al. (2020) Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients with Major Depressive Disorder Who Have Active Suicide Ideation with Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II). The International Journal of Neuropsychopharmacology |
| Fabbri C, Kasper S, Zohar J, et al. (2020) Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 110050 |
| Silberbauer LR, Bartova L, Papageorgiou K, et al. (2020) Oral Ketamine as a Treatment Option in Patients With Treatment Resistant Depression and Comorbid Arterial Hypertension. Journal of Clinical Psychopharmacology. 40: 418-420 |
| Baldinger-Melich P, Gryglewski G, Philippe C, et al. (2020) Corrigendum to "The effect of electroconvulsive therapy on cerebral monoamine oxidase a expression in treatment-resistant depression investigated using positron emission tomography" [Brain Stimul 12 (3) (2019) 714-723]. Brain Stimulation. 13: 1280-1281 |
| Dold M, Bartova L, Kasper S. (2020) Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment. The International Journal of Neuropsychopharmacology |